利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.015 秒)

    SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19
    1.
    发明申请
    SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19 审中-公开

    公开(公告)号：WO2021236415A1

    公开(公告)日：2021-11-25

    申请号：PCT/US2021/032203

    申请日：2021-05-13

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    发明人： HORWITZ, Marcus, A. ,  JIA, Qingmei

    IPC分类号： A61K39/215 ,  A61P31/14 ,  C07K14/165 ,  C07K19/00 ,  C12N5/10

    摘要： Embodiments of the invention include immunogenic compositions that comprise an attenuated recombinant Francisella tularensis subspecies holarctica Live Vaccine Strain (LVS) having a deletion in a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens present on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Embodiments of the invention also include methods of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant Live Vaccine Strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens expressed by a severe acute respiratory syndrome coronavirus 2 (SAR8- CoV-2) polypeptide.

    SAFE POTENT SINGLE PLATFORM VACCINE AGAINST TIER 1 SELECT AGENTS AND OTHER PATHOGENS
    3.
    发明申请
    SAFE POTENT SINGLE PLATFORM VACCINE AGAINST TIER 1 SELECT AGENTS AND OTHER PATHOGENS 审中-公开
    安全强力单平台疫苗对抗1级选择剂和其他病原体

    公开(公告)号：WO2018026729A1

    公开(公告)日：2018-02-08

    申请号：PCT/US2017/044741

    申请日：2017-07-31

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    发明人： HORWITZ, Marcus A. ,  JIA, Qingmei

    IPC分类号： A61K39/114 ,  A61K39/235 ,  A61P37/04 ,  C12N1/21

    摘要： A method of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS AcapB), wherein the LVS AcapB expresses an antigen of at least one pathogen from Table 1; or administering to the host a vaccine that comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1; or administering to the host a prime vaccine and a heterologous booster vaccine where the prime vaccine comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS AcapB), wherein the LVS AcapB expresses an antigen of at least one pathogen from Table 1 and the heterologous booster vaccine comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1.

    摘要翻译： 一种针对病原体免疫易感宿主的方法，包括向宿主施用疫苗，所述疫苗包含缺乏编码CapB的多核苷酸的减毒重组活疫苗菌株（LVS AcapB），其中LVS AcapB表达抗原 的来自表1的至少一种病原体; 或向宿主施用包含表达表1中病原体抗原的减毒单核细胞增生利斯特氏菌的疫苗; 或向宿主施用主疫苗和异源加强疫苗，其中主疫苗包含缺乏编码CapB的多核苷酸的减毒重组活疫苗菌株（LVS AcapB），其中LVS AcapB表达表1中至少一种病原体的抗原，和 异源加强疫苗包含表达表1中病原体抗原的减毒单核细胞增生利斯特氏菌。